Libourne 8th July 2019 - Pig farmers in 12 European countries will now be able to protect their herds against the growing problem of Salmonella Typhimurium. Ceva will launch Salmoporc in Austria, Belgium, Czech Republic, Denmark, Hungary, Ireland, Italy, Netherlands, Portugal, Romania, Slovak Republic, United Kingdom through the remainder of 2019.
Salmoporc has been used on German and Polish farms for over 15 years and has proved to be safe and effective in controlling salmonella. The live attenuated vaccine can be administered orally in piglets and via subcutaneous injection in sows.
"Salmonella in pigs is growing threat and an important zoonotic disease. According to the 2018 European Food Safety Authority (EFSA) report, salmonellosis is the second most reported zoonosis in Europe with over 90.000 cases reported in humans,” said company veterinarian Dr Rike Schmelz.
“Salmonella Typhimurium and monophasic Salmonella Typhimurium represented 17 per cent of confirmed human cases in 2017 so constitutes a major risk to humans.”
Salmoporc is the latest in a line of a number of zoonotic disease vaccines from Ceva, which through its “Together, beyond animal health” vision is committed to protecting people by improving preventative medicine in animals.
About Ceva Santé Animale:
Ceva Santé Animale is a French multinational veterinary pharmaceutical company created in 1999. Chaired by Dr. Marc Prikazsky, Ceva specializes in the research, development, production and marketing of pharmaceutical products and vaccines for livestock (ruminants, swine, poultry) and companion animals.
Ceva is present in 110 countries and employs over 5700 people worldwide. Since 2007, its management and employees have been the majority shareholders in Ceva Santé Animale, which Chairman and CEO is Dr. Marc Prikazsky.
Dr Friederike Schmelz – Expert Animal Health
Martin Mitchell - Communication Director +33 05 57 55 40 80
Martin Looker - BHR Communications + 44 (0)1473 823842